Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Current Deferred Revenue: 2018-2025

Historic Current Deferred Revenue for Arcturus Therapeutics Holdings (ARCT) over the last 7 years, with Sep 2025 value amounting to $6.8 million.

  • Arcturus Therapeutics Holdings' Current Deferred Revenue fell 74.66% to $6.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.8 million, marking a year-over-year decrease of 74.66%. This contributed to the annual value of $19.5 million for FY2024, which is 56.47% down from last year.
  • As of Q3 2025, Arcturus Therapeutics Holdings' Current Deferred Revenue stood at $6.8 million, which was down 39.39% from $11.3 million recorded in Q2 2025.
  • Arcturus Therapeutics Holdings' 5-year Current Deferred Revenue high stood at $71.5 million for Q1 2024, and its period low was $4.7 million during Q3 2022.
  • Over the past 3 years, Arcturus Therapeutics Holdings' median Current Deferred Revenue value was $38.5 million (recorded in 2023), while the average stood at $33.0 million.
  • As far as peak fluctuations go, Arcturus Therapeutics Holdings' Current Deferred Revenue surged by 911.16% in 2021, and later slumped by 91.92% in 2022.
  • Quarterly analysis of 5 years shows Arcturus Therapeutics Holdings' Current Deferred Revenue stood at $43.5 million in 2021, then slumped by 34.12% to $28.6 million in 2022, then surged by 56.48% to $44.8 million in 2023, then tumbled by 56.47% to $19.5 million in 2024, then tumbled by 74.66% to $6.8 million in 2025.
  • Its last three reported values are $6.8 million in Q3 2025, $11.3 million for Q2 2025, and $12.7 million during Q1 2025.